Serum metabolite levels identify incipient metastatic progression of rectal cancer
We observe a distinct serum metabolite profile, in particular involving citrate to the best of our knowledge shown for the first time clinically, in rectal cancer patients at heightened risk of metastasis already when the primary tumour is diagnosed, offering insights into the metabolism of metastatic progression.
Authors
- Sebastian Meltzer (ORCID: https://orcid.org/0000-0001-6640-3927)
- Tonje Bjørnetrø (ORCID: https://orcid.org/0000-0003-2110-5875)
- Anne Hansen Ree (ORCID: https://orcid.org/0000-0002-8264-3223)
- Kine Mari Bakke (ORCID: https://orcid.org/0000-0003-2127-752X)
- Kathrine Røe Redalen (ORCID: https://orcid.org/0000-0002-1172-4632)
- Frode Rise (ORCID: https://orcid.org/0000-0002-7871-3962)
- Paula A. Bousquet (ORCID: https://orcid.org/0000-0002-6653-2195)
- Alistair L. Wilkins
Institutions
- Oslo University Hospital (NO)
- University of Oslo (NO)
- Norwegian University of Science and Technology (NO)
- Akershus University Hospital (NO)
- University of Waikato (NZ)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-04-27
- DOI
- https://doi.org/10.1038/s43856-025-00868-w
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Norges Forskningsråd
- Akershus Universitetssykehus